The U.S. District Court for the District of New Jersey invalidated Eli Lilly and Co.'s method-of-use patent for Strattera, a treatment for ADHD. "Assuming a launch of a generic version of Strattera in the United States, the loss of revenue will undoubtedly add to the challenges we will face during upcoming patent expirations on other key products," CEO John Lechleiter said in a statement.

Full Story:

Related Summaries